Opdivo®

DRUG3 trials

Sponsors

Shandong Boan Biotechnology Co., Ltd, Ono Pharmaceutical Co., Ltd., Shanghai Henlius Biotech

Conditions

Colorectal CancerEsophageal Squamous Cell CarcinomaEsophageal and/or Cardia CancerMelanomaUrothelial Carcinoma (UC)

Phase 1

A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

Not yet recruitingNCT07518043

Shanghai Henlius BiotechEsophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC)

Start: 2026-06-30End: 2028-06-13Target: 174Updated: 2026-04-15

Phase 2

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

RecruitingNCT06948448

Ono Pharmaceutical Co., Ltd.Colorectal Cancer

Start: 2025-11-18End: 2028-10-01Target: 144Updated: 2026-05-18

Phase 3

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

RecruitingNCT06022861

Shandong Boan Biotechnology Co., LtdEsophageal Squamous Cell Carcinoma

Start: 2023-10-12End: 2026-12-31Target: 510Updated: 2024-09-19